gist
“Living reagents” help research and development, and genetically modified animals become mainstream: model animals refer to experimental animals that have been selected and modified to have stable properties, which can reveal the general laws of life science, and are called “living reagents”, which are in the life science industry chain. upstream. With the development of scientific research and the continuous pursuit of new targets, the demand for model animals has developed from ordinary animals to special model animals obtained by artificial breeding, and then to genetically modified animals constructed according to needs. Genetically modified animals can precisely meet user needs and are rapidly developing into mainstream products in the model animal market. According to GMI data, the global genetically modified animal model market size in 2019 was about US$10 billion, and it is expected to increase to US$14.1 billion in 2023, accounting for nearly 67% of the animal model service market.
High investment in research and development, strong demand for model animals: Thanks to the continuous growth of investment in scientific research and new drug research and development, although the Chinese model animal market started late and is small in scale, it has developed rapidly in recent years. my country’s investment in life science research has increased from 43.4 billion yuan in 2015 to over 100 billion yuan in 2021, with a CAGR of nearly 16%; my country’s pharmaceutical research and development is expected to increase from 21.1 billion US dollars in 2019 to 47.6 billion US dollars in 2024. Among them, the market size of experimental mice used for preclinical research and development will reach 3.7 billion yuan in 2030, and the CAGR will be as high as 38.8% in 2019-30. We believe that the growth of China’s model animal market is mainly driven by the expansion of industrial customer demand, thanks to the fact that the growth rate of my country’s preclinical CRO market is higher than that of life science R&D investment.
Iteration of technology and quality control to achieve industrialized supply: In recent years, the emergence of multiple gene editing technologies such as ES cell targeting, Talen, and CRISPR-Cas9 has improved editing efficiency and reduced costs. Technological progress enables model animal suppliers in my country to rapidly develop animal models of different strains. For example, companies such as Yaokang Biology and Nanmo Biology have developed over 10,000 strains and have high market competitiveness. Compared with the independent development of animal models by each laboratory, the supplier has built a large number of animals for many years, has deep accumulation in technology, and has also formed a complete system in quality control, which can stably supply animals in large quantities. In 2019, my country’s animal model market share only accounted for 7% of the global market share, far below the nearly 20% market share of my country’s preclinical CRO market. We believe that with the rapid expansion of strains and substantial increase in production capacity of Chinese model animal suppliers in recent years, their global market share will increase rapidly.
To view the full report click here
Note: Unless it is marked as original, it is all submitted by netizens or institutions for sharing. If you need to publish, please contact [email protected].
This article is reprinted from: https://www.dx2025.com/archives/26604.html
This site is for inclusion only, and the copyright belongs to the original author.